Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cocktail aims to wake up sleeping HIV

NCT ID NCT07635992

Disease control Sponsor: First Affiliated Hospital of Zhejiang University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests whether combining two drugs—ibalizumab and chidamide—can safely reduce the hidden HIV reservoir in people living with HIV. The study will enroll up to 29 adults on stable antiretroviral therapy. Researchers will monitor side effects and measure changes in HIV DNA levels in blood cells.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ibalizumab (monoclonal antibody) and chidamide (histone deacetylase inhibitor)
What this could lead to
If successful, this could point toward a strategy to reduce hidden HIV reservoirs, potentially allowing people with HIV to manage the virus without lifelong daily medication.
What could go wrong
This is a very early Phase 1 trial with only 18-29 participants. It primarily tests safety, not effectiveness. The combination may cause side effects or fail to shrink the viral reservoir significantly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 18 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subjects aged 18-65 years. 2. Confirmed HIV infection by both initial screening assay and Western blot (WB) confirmatory test. 3. Receiving a stable ART regimen for at least 6 months. 4. Viral load below the lower limit of detection. 5. CD4+ T-cell count \>200 cells/mm³. 6. Voluntarily signed the informed consent form and able to comply with regular follow-up visits, specimen collection, and monitoring/treatment of study-related adverse events. 7. Use effective contraception from 4 weeks prior to study initiation until 4 weeks after study completion. Exclusion Criteria: 1. Pregnant or breastfeeding women, or women planning to become pregnant during the study observation period. 2. Subjects with poor treatment adherence. 3. Receipt of immunosuppressants, other immunomodulatory agents, or cytotoxic drugs within 6 months prior to screening. 4. Presence of severe underlying cardiac, cerebral, hepatic, renal, or other systemic diseases; neutrophil count \<1000/mm³; platelet count \<75,000/mm³; allergy to the investigational drug; or other contraindications to treatment. 5. Presence of progressive (or active) malignancy, including but not limited to advanced, metastatic, or unresectable solid tumors or hematologic malignancies. 6. Unwillingness to sign the informed consent form.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV (human immunodeficiency virus) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV (human immunodeficiency virus)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.